GOF advises Scintomics on the sale of its shareholding in PentixaPharm to Eckert & Ziegler

Munich, May 4, 2021 - Gütt Olk Feldhaus (GOF) advised Scintomics GmbH on the sale of its shareholding in PentixaPharm GmbH to Eckert & Ziegler Strahlen- und Medizintechnik AG.

PentixaPharm is developing a radiopharmaceutical combination product against lymphomas and a number of related tumors, which can be used for both diagnosis and therapy of cancer. In February 2021, PentixaPharm had received confirmation from the European Medicines Agency (EMA) that its lead candidate PentixaFor can advance directly into Phase III clinical trials.

Scintomics is developing, licensing and commercializing radiopharmaceutical know-how and radiopharmaceuticals and was a founding shareholder of PentixaPharm.

Eckert & Ziegler is a publicly listed company headquartered in Berlin, Germany, which invests in companies in the fields of medical and isotope technology as well as radiopharmaceuticals and nuclear medicine.

The consideration comprised a cash component as well as listed shares in Eckert & Ziegler. The parties have agreed not to disclose the purchase price.

Legal advisor Scintomics GmbH:

Gütt Olk Feldhaus, Munich: Adrian von Prittwitz (partner, lead), Dr. Ricarda Theis (associate, both Corporate/M&A)

About Gütt Olk Feldhaus:

Gütt Olk Feldhaus is a leading international law firm based in Munich. We provide legal advice on all aspects of commercial and corporate law. We focus on corporate law, M&A, private equity and financing and also handle litigation in these areas.


Adrian von Prittwitz, LL.M.(LSE)
Tel. +49 89 24 22 411 31